Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Cancers·2026

Same author

Efficacy of larotrectinib in pediatric cancers with <i>NTRK</i> gene fusions.

Translational pediatrics·2026

Same author

Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcoma.

Cell death discovery·2025

Same author

MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD.

iScience·2025

Same author

IGSF10 is a RET antagonist regulating Ewing sarcoma growth and GnRH neuron migration.

Cell reports·2025

Search research articles

Related Experiment Video

Updated: Sep 10, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Rhabdomyosarcoma: development of molecular therapeutics under the microscope.

Peter J Houghton¹, Mary-Ann Bjornsti²

¹Department of Molecular Medicine, Greehey Children's Cancer Research Institute, UT Health San Antonio, San Anonio, TX, USA.

Expert Opinion on Therapeutic Targets

|August 21, 2025

Summary

Rhabdomyosarcoma (RMS) is a rare pediatric cancer. Advances reveal molecular targets, but standardized testing is needed for new targeted therapies and improved outcomes in advanced RMS.

Keywords:

Antibody-drug conjugates (ADCs)Fusion-negative (F-N) RMS Fusion-positive (F-P) RMS Rhabdomyosarcoma chimeric antigen receptor (CAR) T-cell therapy mitogen activated protein kinase (MAPK) inhibitors molecular subtypes multikinase inhibitors

More Related Videos

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: Sep 10, 2025

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Area of Science:

Pediatric Oncology
Molecular Pathology
Cancer Therapeutics

Background:

Rhabdomyosarcoma (RMS) is a rare pediatric solid tumor with skeletal muscle characteristics, but its cell of origin is debated.
Current standard treatments (chemotherapy, radiation, surgery) have shown limited improvement for advanced RMS over decades.

Purpose of the Study:

To review recent molecular advances in Rhabdomyosarcoma.
To highlight the need for standardized preclinical testing and molecularly guided clinical trials for novel therapeutics.

Main Methods:

Review of recent research on Rhabdomyosarcoma molecular subtypes and driver mutations.
Analysis of preclinical models and emerging therapeutic strategies, including kinase inhibitors, ADCs, CAR T-cells, and immune checkpoint inhibitors.

Main Results:

Identification of distinct molecular drivers across RMS subtypes suggests potential for targeted therapies.
Numerous molecularly targeted agents show preclinical activity, but efficacy evaluation lacks standardization.

Conclusions:

RMS comprises a group of diseases requiring tailored molecularly targeted treatments.
Development of novel preclinical testing approaches and standardized efficacy assessments is crucial for advancing molecularly guided clinical trials and improving patient outcomes.